Rxsight Inc (RXST) - Total Assets
Based on the latest financial reports, Rxsight Inc (RXST) holds total assets worth $303.99 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Rxsight Inc (RXST) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Rxsight Inc - Total Assets Trend (2019–2025)
This chart illustrates how Rxsight Inc's total assets have evolved over time, based on quarterly financial data. See RXST net assets for net asset value and shareholders' equity analysis.
Rxsight Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Rxsight Inc's total assets of $303.99 Million consist of 92.2% current assets and 7.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.4% |
| Accounts Receivable | $23.38 Million | 7.5% |
| Inventory | $31.56 Million | 10.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Rxsight Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Rxsight Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rxsight Inc's current assets represent 92.2% of total assets in 2025, an increase from 81.7% in 2019.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, down from 7.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 10.1% of total assets.
Rxsight Inc Competitors by Total Assets
Key competitors of Rxsight Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Rxsight Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.20 | 12.68 | 6.80 |
| Quick Ratio | 8.93 | 11.65 | 6.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $251.85 Million | $265.67 Million | $64.44 Million |
Rxsight Inc - Advanced Valuation Insights
This section examines the relationship between Rxsight Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | $311.81 Million |
| Market Capitalization | $228.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Rxsight Inc's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Rxsight Inc's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Rxsight Inc (2019–2025)
The table below shows the annual total assets of Rxsight Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $311.81 Million | -2.12% |
| 2024-12-31 | $318.56 Million | +74.51% |
| 2023-12-31 | $182.55 Million | +21.57% |
| 2022-12-31 | $150.16 Million | -22.08% |
| 2021-12-31 | $192.72 Million | +91.43% |
| 2020-12-31 | $100.68 Million | -8.83% |
| 2019-12-31 | $110.43 Million | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more